Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hamps BioBOM:544312 -2.17%13 EV-to-FCF is -4.45 as of Aug. 20, 2026. GuruFocus rates BOM:544312 with a GF Score™ of 13/100. The stock has 4 warning signs investors should review. Among 409 Healthcare Providers & Services companies, Hamps Bio ranks worse than 244498.53% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Hamps Bio's Enterprise Value is ₹263.15 Mil.
Hamps Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-59.11 Mil. Therefore, Hamps Bio's EV-to-FCF for today is -4.45.
The historical rank and industry rank for Hamps Bio's EV-to-FCF or its related term are showing as below:
BOM:544312'
s EV-to-FCF Range Over the Past 10 Years
Min: -69.33 Med: -4.57 Max: -3.15
Current: -4.75
During the past 5 years, the highest EV-to-FCF of Hamps Bio was -3.15. The lowest was -69.33. And the median was -4.57.
BOM:544312's EV-to-FCF is ranked worse than 100% of 409
companies
in the Healthcare Providers & Services industry
Industry Median: 18.28
vs BOM:544312: -4.75
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hamps Bio's share price for today is ₹22.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hamps Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-0.840.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Hamps Bio EV-to-FCF Related Terms
Hamps Bio EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Hamps Bio's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Hamps Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hamps Bio EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Hamps Bio's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Hamps Bio's EV-to-FCF falls into.
Hamps Bio's current Enterprise Value is ₹263.15 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hamps Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-59.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hamps Bio (BOM:544312) has a EV-to-FCF of -4.45 as of Aug. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hamps Bio and its competitors. According to the industry distribution chart, Hamps Bio ranks #999999 out of 409 companies in the Healthcare Providers & Services industry.
Is Hamps Bio's EV-to-FCF too high?
Hamps Bio's current EV-to-FCF is -4.45. Based on the distribution chart, Hamps Bio ranks #999999 out of 409 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Hamps Bio has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Hamps Bio's EV-to-FCF compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Hamps Bio ranks #999999 out of 409 companies for EV-to-FCF. This places Hamps Bio in the lower half of its industry. The industry median EV-to-FCF is 18.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 18.28, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hamps Bio and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 18.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hamps Bio's current EV-to-FCF is -4.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hamps Bio stock overvalued right now?
Hamps Bio (BOM:544312) has a current EV-to-FCF of -4.45. The current EV-to-FCF is -4.45. Hamps Bio's overall GF Score™ is 13/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Hamps Bio (BOM:544312), the current EV-to-FCF is -4.45 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hamps Bio Ltd is engaged in the ethical marketing and distribution of pharmaceutical formulation products. Its product include tablets, syrups, capsules, injectables, oil, gel and powder used as medicine and nutrition supplements as well as the manufacturing of freeze dried and frozen products such as fruits, vegetables, herbs and flowers. The company segment includes Manufacturing, trading and distribution of Pharmaceutical formulation products and Manufacturing of Freeze dried and frozen products like fruits, vegetables, herbs, flowers, etc. Key revenue is generated from Medicine Products.
13GF Score
Get the complete analysis for BOM:544312
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544312 has been successfully added to your 
